Aspire Biopharma Holdings Inc (ASBP)

$0.10 +0.00 (2.21%)
Market Cap 10.20M
Revenue (ttm) 0.00
Net Income (ttm) -12.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.54
Volume 3,900,700
Avg Vol 33,741,039
Day's Range N/A - N/A
Shares Out 107.48M
Stochastic %K 26%
Beta 0.86
Analysts Strong Buy
Price Target N/A

Company Profile

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testos...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 592 7399
Address:
23150 Fashion Drive, Suite 232, Estero, United States
Lifestaylaluxuryy
Lifestaylaluxuryy Dec. 25 at 4:37 PM
$ASBP Aspire Biopharma holding Hold onto your seats, this is next-level drug delivery! 💉 Needle-free sublingual aspirin → therapeutic levels in 2 minutes! ⚡ 4-5x faster than chewed aspirin. Skips GI & liver → safer, cleaner. 🌐 Targeting $100B+ global drug delivery market. 🤝 Big pharma like Bayer, Pfizer, Tylenol are watching. 📈 Licensing, acquisitions & expansion into insulin, Semaglutide & more. ✅ FDA already shows positive signals, NDA path in motion. 🔥 This could be a game-changer in cardiovascular care and beyond. 1982 of us are ready. Are you? ⏳ Countdown to impact: FDA response by Jan 2 – mark your calendars!
0 · Reply
WorsttradereverBadluck
WorsttradereverBadluck Dec. 25 at 2:24 PM
$ASBP
0 · Reply
codeben
codeben Dec. 24 at 10:43 PM
$ASBP
6 · Reply
WorsttradereverBadluck
WorsttradereverBadluck Dec. 24 at 10:19 PM
$ASBP some one manage to buy over 600.000 shares today at low 0.9xx$
1 · Reply
MegaTrade22
MegaTrade22 Dec. 24 at 9:26 PM
$ASBP Placing my order
0 · Reply
izjustlooking
izjustlooking Dec. 24 at 9:02 PM
$ASBP enjoy the holidays - back Friday. Hopefully going upwards and onwards
0 · Reply
MegaTrade22
MegaTrade22 Dec. 24 at 8:33 PM
$ASBP Anyone who’s here longer than me with good DD hmu. I got some questions yet I also have some important feedback you’d be interested! Wishing everyone a Merry Christmas Eve 🎄
0 · Reply
Rowdy_Ruckus
Rowdy_Ruckus Dec. 24 at 8:24 PM
$ASBP maybe an after market Xmas miracle!?!
0 · Reply
METS1
METS1 Dec. 24 at 8:10 PM
$ASBP I think we may have hit our bottom here. I believe also more people might come in an invest in ASBP, because they also think the FDA will give they approval of ASBP patent by Jan 2nd and the stock will go up in instantly. My opinion
1 · Reply
MegaTrade22
MegaTrade22 Dec. 24 at 7:24 PM
$ASBP Strong close & a day closer to FDA feedback 🤞
1 · Reply
Latest News on ASBP
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Dec 18, 2025, 8:30 AM EST - 7 days ago

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Dec 12, 2025, 5:00 PM EST - 12 days ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Aspire Biopharma Provides Q3 2025 Business Update

Dec 4, 2025, 9:00 AM EST - 21 days ago

Aspire Biopharma Provides Q3 2025 Business Update

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Dec 2, 2025, 9:00 AM EST - 23 days ago

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Nov 26, 2025, 9:00 AM EST - 4 weeks ago

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Nov 6, 2025, 9:00 AM EST - 7 weeks ago

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Oct 6, 2025, 8:30 AM EDT - 2 months ago

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Oct 3, 2025, 11:30 AM EDT - 2 months ago

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher

Oct 2, 2025, 2:44 PM EDT - 2 months ago

Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Oct 1, 2025, 8:30 AM EDT - 3 months ago

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Sep 17, 2025, 8:30 AM EDT - 3 months ago

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Sep 16, 2025, 8:30 AM EDT - 3 months ago

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Sep 3, 2025, 8:30 AM EDT - 4 months ago

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aug 18, 2025, 8:30 AM EDT - 4 months ago

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aug 14, 2025, 8:00 AM EDT - 4 months ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aug 13, 2025, 9:10 AM EDT - 4 months ago

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Jul 31, 2025, 8:30 AM EDT - 5 months ago

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Jul 30, 2025, 7:45 PM EDT - 5 months ago

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Jul 22, 2025, 10:45 AM EDT - 5 months ago

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Jul 9, 2025, 8:30 AM EDT - 6 months ago

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Jun 24, 2025, 8:30 AM EDT - 6 months ago

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Jun 10, 2025, 8:30 AM EDT - 7 months ago

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

May 28, 2025, 8:30 AM EDT - 7 months ago

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

May 20, 2025, 8:30 AM EDT - 7 months ago

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

May 8, 2025, 8:00 AM EDT - 8 months ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Apr 29, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Apr 14, 2025, 8:30 AM EDT - 9 months ago

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Apr 11, 2025, 8:30 AM EDT - 9 months ago

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Apr 9, 2025, 8:30 AM EDT - 9 months ago

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Mar 20, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

Mar 13, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

Mar 11, 2025, 8:00 AM EDT - 10 months ago

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Mar 3, 2025, 7:30 AM EST - 10 months ago

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Feb 25, 2025, 7:30 AM EST - 10 months ago

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

Feb 20, 2025, 6:15 PM EST - 10 months ago

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

Lifestaylaluxuryy
Lifestaylaluxuryy Dec. 25 at 4:37 PM
$ASBP Aspire Biopharma holding Hold onto your seats, this is next-level drug delivery! 💉 Needle-free sublingual aspirin → therapeutic levels in 2 minutes! ⚡ 4-5x faster than chewed aspirin. Skips GI & liver → safer, cleaner. 🌐 Targeting $100B+ global drug delivery market. 🤝 Big pharma like Bayer, Pfizer, Tylenol are watching. 📈 Licensing, acquisitions & expansion into insulin, Semaglutide & more. ✅ FDA already shows positive signals, NDA path in motion. 🔥 This could be a game-changer in cardiovascular care and beyond. 1982 of us are ready. Are you? ⏳ Countdown to impact: FDA response by Jan 2 – mark your calendars!
0 · Reply
WorsttradereverBadluck
WorsttradereverBadluck Dec. 25 at 2:24 PM
$ASBP
0 · Reply
codeben
codeben Dec. 24 at 10:43 PM
$ASBP
6 · Reply
WorsttradereverBadluck
WorsttradereverBadluck Dec. 24 at 10:19 PM
$ASBP some one manage to buy over 600.000 shares today at low 0.9xx$
1 · Reply
MegaTrade22
MegaTrade22 Dec. 24 at 9:26 PM
$ASBP Placing my order
0 · Reply
izjustlooking
izjustlooking Dec. 24 at 9:02 PM
$ASBP enjoy the holidays - back Friday. Hopefully going upwards and onwards
0 · Reply
MegaTrade22
MegaTrade22 Dec. 24 at 8:33 PM
$ASBP Anyone who’s here longer than me with good DD hmu. I got some questions yet I also have some important feedback you’d be interested! Wishing everyone a Merry Christmas Eve 🎄
0 · Reply
Rowdy_Ruckus
Rowdy_Ruckus Dec. 24 at 8:24 PM
$ASBP maybe an after market Xmas miracle!?!
0 · Reply
METS1
METS1 Dec. 24 at 8:10 PM
$ASBP I think we may have hit our bottom here. I believe also more people might come in an invest in ASBP, because they also think the FDA will give they approval of ASBP patent by Jan 2nd and the stock will go up in instantly. My opinion
1 · Reply
MegaTrade22
MegaTrade22 Dec. 24 at 7:24 PM
$ASBP Strong close & a day closer to FDA feedback 🤞
1 · Reply
Stockmarketmaker
Stockmarketmaker Dec. 24 at 6:00 PM
$ASBP nice close
1 · Reply
Razied
Razied Dec. 24 at 6:00 PM
$ASBP annnnd we are green baby.
0 · Reply
Pennystockmadness
Pennystockmadness Dec. 24 at 5:59 PM
$ASBP if this turns green we could see $.10+
1 · Reply
Jmk1985
Jmk1985 Dec. 24 at 5:18 PM
$ASBP did the same 🤝🏽 thanks for the Xmas cheapies
2 · Reply
MegaTrade22
MegaTrade22 Dec. 24 at 5:16 PM
$ASBP 20k slap
0 · Reply
Psikus
Psikus Dec. 24 at 5:15 PM
$ASBP It’s so fucking uncomfortable to carry bags on this stock with 60% loss. I have a feeling that we all got played on this one. I hope I’m wrong. Merry Christmas to all of you guys.
1 · Reply
Pennystockmadness
Pennystockmadness Dec. 24 at 5:12 PM
$ASBP someone just tried intimidation by putting 150,000 shares for sale at .0913. Got eaten right up lol!!! All in!!!!
0 · Reply
Mychael30
Mychael30 Dec. 24 at 4:27 PM
$ASBP officially holding 25k
0 · Reply
Tank510
Tank510 Dec. 24 at 3:58 PM
$ASBP Fish on
0 · Reply
Pennystockmadness
Pennystockmadness Dec. 24 at 3:41 PM
$ASBP 😂😂😂😂😂😂they have 2 years cash lolol. Good one!
1 · Reply
Mkt_predictor
Mkt_predictor Dec. 24 at 3:33 PM
$ASBP Buying is drying up but the supply is millions and millions more. watch for a collapse soon.
2 · Reply
Mkt_predictor
Mkt_predictor Dec. 24 at 3:29 PM
$ASBP .08s coming, dilution machine in full effect here
1 · Reply